Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas.
about
Tissue patterning and cellular mechanicsNon-muscle myosin II in disease: mechanisms and therapeutic opportunitiesEarly events in cell spreading as a model for quantitative analysis of biomechanical eventsCompetition for actin between two distinct F-actin networks defines a bistable switch for cell polarization.Regulated lysosomal exocytosis mediates cancer progressionComprehensive mutation profiling of mucinous gastric carcinoma.CRISPR-Cas9: from Genome Editing to Cancer ResearchGender-Specific Molecular and Clinical Features Underlie Malignant Pleural MesotheliomaCRISPR-Cas9 knockin mice for genome editing and cancer modelingMyosin light chain kinase regulates cell polarization independently of membrane tension or Rho kinase.SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic markerAn In Vivo Gain-of-Function Screen Identifies the Williams-Beuren Syndrome Gene GTF2IRD1 as a Mammary Tumor Promoter.Life without double-headed non-muscle myosin II motor proteins.Identification of drivers from cancer genome diversity in hepatocellular carcinoma.Genome-wide CRISPR screen in a mouse model of tumor growth and metastasisRNAi therapies: drugging the undruggable.Non-muscle myosins in tumor progression, cancer cell invasion, and metastasis.CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinomaThe role of vertebrate nonmuscle Myosin II in development and human disease.Pharmacological activation of myosin II paralogs to correct cell mechanics defects.Drugging the undruggable RAS: Mission possible?Emerging interactions between skin stem cells and their niches.A pooled shRNA screen for regulators of primary mammary stem and progenitor cells identifies roles for Asap1 and Prox1.Four things to know about myosin light chains as reporters for non-muscle myosin-2 dynamics in live cells.High-throughput functional genomics using CRISPR-Cas9.Myosin II isoform co-assembly and differential regulation in mammalian systemsEfficient inhibition of tumor angiogenesis and growth by a synthetic peptide blocking S100A4-methionine aminopeptidase 2 interaction.Strand-specific in vivo screen of cancer-associated miRNAs unveils a role for miR-21(∗) in SCC progression.Conditional deletion of nonmuscle myosin II-A in mouse tongue epithelium results in squamous cell carcinomapiggyBac mediates efficient in vivo CRISPR library screening for tumorigenesis in miceScreening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma.Expression and prognostic significance of MYL9 in esophageal squamous cell carcinoma.Triple-Layered pH-Responsive Micelleplexes Loaded with siRNA and Cisplatin Prodrug for NF-Kappa B Targeted Treatment of Metastatic Breast Cancer.Onco-Golgi: Is Fragmentation a Gate to Cancer Progression?Advances in computational approaches for prioritizing driver mutations and significantly mutated genes in cancer genomesNuclear lamins in cancerMyosin 1e promotes breast cancer malignancy by enhancing tumor cell proliferation and stimulating tumor cell de-differentiation.MYH9 binds to lncRNA gene PTCSC2 and regulates FOXE1 in the 9q22 thyroid cancer risk locus.Substrate Stiffness Influences Doxorubicin-Induced p53 Activation via ROCK2 Expression.RNAi in the mouse: rapid and affordable gene function studies in a vertebrate system.
P2860
Q26778749-4950A5C8-00F6-42C2-9C7C-50B9AD7318EAQ26778962-8F0FEB0C-CB26-47FB-93FE-554F9CFAA10AQ26821973-53C30F57-423D-45F6-A517-AA698E9BB473Q27312648-6DB32327-17B3-4D47-8167-AB54C7746B14Q27339507-ADF9E006-9459-4E6E-9D80-56C467B3B111Q27853392-01080681-B63C-42D6-92F8-94CA03F9D8AFQ28066263-59B7A015-37ED-4BC2-92DE-369CAB891417Q28384371-1E1449FC-D889-4923-A6B4-510CB438A146Q30607892-2DE0059B-9FE9-44CA-B0A6-A497BD3B09A3Q30644151-3F30D52A-8BA1-45CF-8839-0A1EDD707DBCQ33576879-9E73A145-8FE6-46E3-A81D-6C8EB1887B31Q33623668-3B8A4618-491F-4D78-8BFF-416F6C95D0E8Q33852054-263C48E0-52C7-4001-AF44-15B114A7351EQ33907993-ECCA4010-208F-4210-A8CD-F2F67532BB5BQ34043392-37E4B221-54F5-40E8-8156-BE2CD07BE215Q34131220-65C46A5A-03AB-427A-8853-C90C8A16ACF1Q34207052-A305F4C3-9348-4329-8308-7DDE737287DAQ34342934-8E1831EA-C8C3-489E-9A13-7D992BDC6E9BQ34362453-8B7C29CA-ECFA-4E8A-9260-68E2981C58CDQ35062582-F6658DD4-6BC8-416A-B397-1267B23F5362Q35163434-17B81FDE-6D69-4DCA-8E5C-7290A44975DCQ35174984-40DD98D7-80F4-4481-9DD3-A856D7547EACQ35441295-2DAFEA2D-67A1-40EA-BF9A-F1C2F1574100Q35449974-4EEF42B7-790B-43BC-BDF6-00CA56218E53Q35597703-CEE5DC20-722C-49F1-AB88-FFF96E819595Q35613068-530448AD-BAF8-475D-B395-C5D36106CB53Q35651091-539C5B0A-37DA-4255-BEC7-3525A878380FQ35855855-960BB775-8576-40BB-99DC-4B003B000A46Q36067924-FFF53E0E-E218-450C-B4BD-65E655C50B47Q36243531-57EE4DDD-BA33-434F-9B52-9C27F8B3EC5BQ36331953-5CF45FBC-27BE-43FD-9FC0-CBC343C434DCQ36340056-E91E5CA9-5900-4FF4-B6B5-F9F531AE6532Q36372323-C7447DCA-D287-4A66-9E7D-E70D29CBDEFAQ36776494-9809EB8B-CF46-4929-BF88-7E36D470744AQ37096363-85252CD6-19B5-4764-8FE4-CA6ABF15059FQ37207687-9B2F3F68-53D4-4990-90E6-04055F1B69EDQ37564758-6873537D-4787-44D2-AC2E-39B45A469622Q37599009-D8AB5651-7148-4805-86A4-BDE4EA29894FQ37612047-807F6A63-D9E0-4CB0-8E22-20F892932253Q38268543-42B84348-D926-4967-8E63-6CE6170B67A6
P2860
Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Direct in vivo RNAi screen unv ...... r of squamous cell carcinomas.
@en
Direct in vivo RNAi screen unv ...... r of squamous cell carcinomas.
@nl
type
label
Direct in vivo RNAi screen unv ...... r of squamous cell carcinomas.
@en
Direct in vivo RNAi screen unv ...... r of squamous cell carcinomas.
@nl
prefLabel
Direct in vivo RNAi screen unv ...... r of squamous cell carcinomas.
@en
Direct in vivo RNAi screen unv ...... r of squamous cell carcinomas.
@nl
P2093
P2860
P356
P1433
P1476
Direct in vivo RNAi screen unv ...... r of squamous cell carcinomas.
@en
P2093
Ataman Sendoel
Boris Reva
Daniel Oristian
Daniel Schramek
Evan Heller
Jeremy P Segal
Slobodan Beronja
P2860
P304
P356
10.1126/SCIENCE.1248627
P407
P50
P577
2014-01-01T00:00:00Z